# Kevin Johnson

> Kevin Johnson is a seed investor at Medicxi (London) backing Biotechnology and Medical. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Medicxi](https://shizune.co/investors/profile/medicxi-ventures)
- Location: London, United Kingdom
- Total investments: 6
- Lead investor: 67%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/kevin-johnson/0/a20/670
- Facebook: https://web.facebook.com/kevin.johnson.77770194?fref=ts

Kevin Johnson is a seed investor at Medicxi in London focused on Biotechnology and Medical. Prior to co-founding Medicxi Ventures, Kevin was a partner with Index Ventures for 12 years, having joined the firm’s life sciences team in 2003. Kevin spearheaded Index’very first experimental asset-centric investment, in PanGenetics, which was later acquired by Abbott Pharmaceuticals. He was formerly on the board of directors of Versartis(Nasdaq: VSAR) and is currently involved with include Acutus and Levicept among others.Prior to joining Index, Kevin was with Cambridge Antibody Technology (CAT), where he was appointed Head of Research in 1994 and, in 1997, Research Director and Chief Technology Officer. He led the development of CAT's platform technologies and their application in the discovery of a number of human antibodies, two of which are now on the market: Humira (Abbott Pharmaceuticals) and Benlysta (GlaxoSmithKline). Kevin was part of the management team that floated CAT on the London Stock Exchange; it was subsequently acquired by AstraZeneca.Kevin received a BSc in Molecular Biology from Edinburgh University and a PhD in Pathology from Cambridge University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 50% |
| Medical | 2 | 33% |
| Health Care | 2 | 33% |
| Pharmaceutical | 2 | 33% |
| Manufacturing | 1 | 17% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 33% |
| Series A | 2 | 33% |
| Series B | 2 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 33% |
| Switzerland | 1 | 17% |
| The Netherlands | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Acutus Medical | Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists.Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Itsproducts are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals.It was founded in 2011 and headquartered in Carlsbad, California. | $28M | Series B | Aug 20, 2013 |  |
| Molecular Partners | Molecular Partners is a clinical-stage biopharmaceutical company working to advance modern medicine and significantly improve the management of serious diseases. They are developing a powerful new class of potent, specific and versatile small protein therapies called DARPin® therapeutics. | $44.2M | Series B | Dec 16, 2009 |  |
| Molecular Partners | Molecular Partners is a clinical-stage biopharmaceutical company working to advance modern medicine and significantly improve the management of serious diseases. They are developing a powerful new class of potent, specific and versatile small protein therapies called DARPin® therapeutics. | $15.6M | Series A | Aug 14, 2007 |  |
| Impact Biomedicines | Impact Biomedicines is pioneering the development of life changing treatments for patients with complex cancers. The Company’s pipeline is centered around fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor that is being developed initially for the treatment of myelofibrosis and polycythemia vera. | $22M | Series A |  |  |
| PanGenetics | PanGenetics B.V. develops monoclonal antibodies for the treatment of immune mediated diseases.PanGenetics is a clinical development company that specializes in taking antibodies from the late research stage through to clinical proof of concept. The company is based in Utrecht, the Netherlands with an office in Cambridge, UK. PanGenetics employsa lean business model with manufacturing and clinical development activities outsourced to specialist providers. Apart from PG110, the other clinical program of PanGenetics is PG102, a CD40 antagonist for treatment of autoimmune diseases which is currently being evaluated in a clinical study in psoriatic arthritis patients | $2M | Seed |  |  |
| Acutus Medical | Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists.Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Itsproducts are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals.It was founded in 2011 and headquartered in Carlsbad, California. | $1M | Seed |  |  |

6 of 6 investments shown.

## Co-investors
- [BB Biotech Ventures](https://shizune.co/investors/profile/bb-biotech-ventures) — VC Fund, 2 deals together
- [Endeavour Vision](https://shizune.co/investors/profile/endeavour-vision) — VC Fund, 2 deals together
- [Johnson & Johnson Development Corporation](https://shizune.co/investors/profile/johnson-johnson-development-corporation) — VC Fund, 2 deals together
- [Advent Venture Partners](https://shizune.co/investors/profile/advent-venture-partners) — VC Fund, 1 deal together
- [GE Ventures](https://shizune.co/investors/profile/ge-ventures) — VC Fund, 1 deal together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 1 deal together

## About Medicxi

VC Fund · London, United Kingdom

Medicxi is an investment firm that focuses on the life sciences sector. It was established in 2016 by the former Index Ventures life sciences team, who have been active for over 20 years and have significant experience in drug discovery and the development of therapeutics for unmet medical needs.

5 contacts available at Medicxi.

| Name | Title | Profile |
| --- | --- | --- |
| Giovanni Pericolini | Finance Director & CFO | https://shizune.co/investors/profile/giovanni-pericolini |
| Kevin Johnson | Co-Founder & Partner | https://shizune.co/investors/profile/kevin-johnson-8 |
| Mark Boer | Member of the Board of Advisors | https://shizune.co/investors/profile/mark-de-boer |
| Michele Bauer | Co-Founder & Partner | https://shizune.co/investors/profile/michele-ollier |
| Trevor Baglin | Venture Partner | https://shizune.co/investors/profile/trevor-baglin |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Kevin Johnson invest in?

Kevin Johnson invests primarily in Biotechnology, Medical and Health Care startups, most often at Seed and Series A stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co